Abstract:PL07-02 Purpose: Genetic polymorphisms contribute to interindividual variation in drug response. Understanding how specific genetic variants modify drug action pathways may provide informative blueprints for individualized chemotherapy. However, a single polymorphism is likely to exhibit a modest effect. Therefore, we applied a pathway-based approach to evaluate the cumulative effect of multiple polymorphisms on clinical outcome of patients with non-small cell lung cancer (NSCLC). Methods: We genotyped 25 functional polymorphisms in 16 key genes involved in cisplatin metabolism and drug action and evaluated their associations with overall survival in 229 NSCLC patients receiving first-line cisplatin-based chemotherapy. The Cox proportional hazard model was used to assess the effect of individual polymorphisms on overall survival, Kaplan-Meier curves and log-rank tests were used to assess the differences in survival by individual polymorphisms. We then performed a pathway-based analysis by counting the number of putative unfavorable genotypes. Survival tree analyses using recursive-partitioning were also performed to investigate higher order gene-gene interactions and identify subgroups of individuals at higher risk of death. We finally constructed receiver operating characteristic (ROC) curves and calculated the area under the curve (AUC) to evaluate the specificity and sensitivity of predicting death and survival by clinical variables only, and by the combination of clinical, epidemiological, and genetic variables. Results: Several biologically plausible main effects were identified in individual analysis. Among nucleotide excision repair (NER) pathway genes, patients carrying the rare homozygous RAD23 Ala249Val genotype exhibited significantly poorer survival (HR= 2.08, 95% CI, 1.04 to 4.16). An ERCC1 3’ UTR SNP (rs3212986) variant-containing genotypes (GT+TT) exhibited significantly improved overall survival (HR=0.68, 95%CI, 0.48-0.95). Kaplan-Meier estimates demonstrated that the median survival time (MST) for individuals with the ERCC1 GT+TT genotypes was 15.8 months compared with MST for the wild-type GG genotype of 12.1 months. We then assumed an additive model and summed the unfavorable genotypes in the NER pathway. These unfavorable genotypes were XPA 5’ UTR A23G (AG/GG), XPC intron9 poly-AT (-), XPD Lys751Gln (AA/AC), CCNH Val270Ala (TT/TC), RAD23 (TT), and ERCC1 (GG). There was a trend of reduced risk of death with decreasing number of unfavorable genotypes. Compared with patients >4 unfavorable genotypes, the HRs for patients with 3-4, and 4, 3 to 4, and 1.2). Kaplan-Meier estimates were plotted for three representative nodes selected from each risk group. Terminal node 1 was in the low-risk group with a MST of 22.6 months, terminal node 3 was in the medium-risk group with a MST of 17.7 months, and terminal node 4 was in the high-risk group with a MST of 9.27 months (log rank P 4) and used Kaplan-Meier survival curves to plot three representative nodes from each risk group. The MST was 78.5 months for terminal node 1 in the low-risk group, 15.1 months for terminal node 10 in the medium-risk group, and 6.7 months for terminal node 9 in the high-risk group (log rank P

Exploring Genetic Variants and Platinum Chemotherapy Response in Indonesian Non-Small Cell Lung Cancer Patients: Insights from ERCC2 rs13181

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

Genetic Variants in ERCC1 and XPC Predict Survival Outcome of Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Therapy

Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review

Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer

DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy

Genetic Variants Associated With Response to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer Patients: A Field Synopsis and Meta‐Analysis

Single-nucleotide polymorphisms of nucleotide excision repair genes and their association with overall survival in North Indian lung cancer patients treated with platinum-based doublet chemotherapy

Association Of Base Excision Repair Gene Polymorphisms With Response To Chemotherapy Of Advanced Non Small-Cell Lung Cancer In A Chinese Population.

ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer

Single Nucleotide Polymorphism in ERCC1 118C→T Predicts the Outcome of NSCLC Patients Receiving Platinum-Based Chemotherapy

Methylenetetrahydrofolate Reductase C677T Polymorphism Predicts Response and Time to Progression to Gemcitabine-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer in a Chinese Han Population

Genetic Variants Of Nbs1 Predict Clinical Outcome Of Platinum-Based Chemotherapy In Advanced Non-Small Cell Lung Cancer In Chinese

Genetic Variants in Nucleotide Excision Repair Pathway Predict Survival of Esophageal Squamous Cell Cancer Patients Receiving Platinum‐based Chemotherapy

Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer

Germline Predictors of Outcome in Non-small Cell Lung Cancer

Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer

Genetic Polymorphisms and Treatment Response in Advanced Non-Small Cell Lung Cancer.

Ethnic Differences, Lung Cancer Risk, and Association of NRF2 Gene Polymorphism with Gemcitabine-Based Chemotherapy

Association of ERCC1-C118T and -C8092A Polymorphisms with Lung Cancer Risk and Survival of Advanced-Stage Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy: a Pooled Analysis Based on 39 Reports.

Single Nucleotide Polymorphisms in XRCC1 and Clinical Response to Platin-based Chemotherapy in Advanced Non-small Cell Lung Cancer